Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Outpatient (ex Primary Care)

 

Where to look for green shoots in health care M&A

M&A in European health care has been almost at a standstill in H1 2023, as the chasm between the price expectations of buyers and sellers has grown. HBI asks if the prospects look better for H2 and beyond, with the help of market experts.

Markets in Middle East and India on brink of maturity

The private healthcare markets in major Indian and middle eastern cities are on the brink of becoming mature according to a consulting source, and this will require operators and investors to take a different approach.

Interview: Jason Powell, Co-CEO, UK Vein Clinic Group 

We look at how to build a dynamic, low-cost outpatient chain which delivers high quality care and at the UK venous market more generally with Jason Powell, whose UK Vein Clinic Group looks set to grow revenue 50% in 2024, after doubling sales in 2023.  

Amanat loses a CEO, and gains a platform

UAE-based listed health care and education investment firm Amanat Holdings has had an interesting few weeks. First, its high-flying CEO departed the group, allegedly by mutual consent - but without an immediate successor. Now Amanat has announced it is consolidating its healthcare assets into a single platform.

Interview: Jose Bailey, commercial director, CHEC

UK-based and NHS focused ophthalmology group CHEC is branching out - expanding its offering, going private in Wales, and diversifying into endoscopy with new dual purpose clinics. HBI chats with Jose Bailey, commercial director, to find out more.

Interview: Sam Gray, Apposite Capital

London-based PE group Apposite Capital is among the most active investors in health care in Europe. HBI chats with managing partner Sam Gray about the state of the market and pricing, how he sees that changing, and the investment opportunities piquing his interest at present.

Legal challenges may derail German investor crackdown

HBI hears German health minister Karl Lauterbach’s plan to stop “locust investors” from buying up outpatient facilities may be shot down by a double whammy of legal and political considerations. HBI speaks to a Germany-based lawyer and healthcare expert to find out more.

Find Us